Clinical Trials and Studies

Now Enrolling People with Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) For A Research Study

Study Title:
Phase 2 ALXN1210-NEPH-202 Study (clinicaltrials.gov NCT04564339)

Study Sponsor:
Alexion, Astra Zeneca Rare Disease

Purpose of Study:
The purpose of this clinical trial is to evaluate the safety and efficacy (effectiveness against disease) of the study medication (ALXN1210 also known as ravulizumab or ULTOMIRIS ®) in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease.

What Does this Study Involve?
This study will include 120 participants, 60 with LN and 60 with IgAN. The total study duration for each participant will be approximately 2 years.

This clinical trial is a phase 2 randomized placebo controlled clinical trial that is randomized 2:1 treatment to placebo such that if you are enrolled you are twice as likely to receive the study treatment than the placebo.

Before you choose to participate, you should speak with your doctor.

You May Qualify for This Study If You Are:
• Between 18 and 75 years of age
• Diagnosed with LN or IgAN based on a kidney biopsy
• Have protein in your urine (equal to or more than 1gram/day)
• Have kidney function with eGFR >/= 30 mL/min/1.73m2
• Willing to complete 24-hour urine collections (collection of urine over a 24-hour period to assess for protein, which can be scheduled in advance and can be done at home)
• Willing to use reliable form of contraception (birth control)

If you have any of the following, you may not be able to participate in the study:
• Kidney or other organ transplant
• History of meningitis infection (Neisseria meningitis)
• Pregnant or breast-feeding

Study Type:
– Phase II
– Randomized
– Placebo controlled

Learn More by visiting www.clinicaltrials.gov using reference number NCT04564339 or call Alexion at 855-752-2356 or email clinicaltrials@alexion.com.